Regeneron Pharmaceuticals Inc. (REGN): Price and Financial Metrics

Regeneron Pharmaceuticals Inc. (REGN): $840.54

19.64 (+2.39%)

POWR Rating

Component Grades








Add REGN to Watchlist
Sign Up

Industry: Biotech




#12 of 346

in industry

REGN Price/Volume Stats

Current price $840.54 52-week high $853.97
Prev. close $820.90 52-week low $668.00
Day low $824.22 Volume 220,980
Day high $840.54 Avg. volume 559,322
50-day MA $812.97 Dividend yield N/A
200-day MA $785.67 Market Cap 91.57B

REGN Stock Price Chart Interactive Chart >


  • Quality is the dimension where REGN ranks best; there it ranks ahead of 87% of US stocks.
  • REGN's strongest trending metric is Growth; it's been moving down over the last 177 days.
  • REGN ranks lowest in Momentum; there it ranks in the 15th percentile.

REGN Stock Summary

  • With a market capitalization of $88,776,539,382, REGENERON PHARMACEUTICALS INC has a greater market value than 97.31% of US stocks.
  • With a price/sales ratio of 6.78, REGENERON PHARMACEUTICALS INC has a higher such ratio than 85.12% of stocks in our set.
  • The volatility of REGENERON PHARMACEUTICALS INC's share price is greater than that of only 6.98% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to REGN, based on their financial statements, market capitalization, and price volatility, are LRCX, ANET, CDNS, KLAC, and VRTX.
  • REGN's SEC filings can be seen here. And to visit REGENERON PHARMACEUTICALS INC's official web site, go to

REGN Valuation Summary

  • REGN's price/sales ratio is 6.7; this is 262.16% higher than that of the median Healthcare stock.
  • Over the past 243 months, REGN's price/sales ratio has gone down 10.

Below are key valuation metrics over time for REGN.

Stock Date P/S P/B P/E EV/EBIT
REGN 2023-11-20 6.7 3.5 21.9 19.8
REGN 2023-11-17 6.7 3.5 21.9 19.8
REGN 2023-11-16 6.6 3.5 21.7 19.6
REGN 2023-11-15 6.6 3.5 21.6 19.5
REGN 2023-11-14 6.6 3.5 21.7 19.6
REGN 2023-11-13 6.6 3.5 21.7 19.6

REGN Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 228.92%.
  • The 4 year net cashflow from operations growth rate now stands at 23.95%.
  • Its 5 year price growth rate is now at 32.25%.
REGN's revenue has moved up $4,193,100,000 over the prior 34 months.

The table below shows REGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 12,172.9 5,014.9 4,338.4
2022-09-30 13,710.2 5,667.5 5,370.3
2022-06-30 14,226.8 8,452.2 5,686.8
2022-03-31 16,508.1 8,514.5 7,933.6
2021-12-31 16,071.7 7,081.3 8,075.3
2021-09-30 13,542.9 5,939.8 6,995.5

REGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • REGN has a Quality Grade of B, ranking ahead of 86.94% of graded US stocks.
  • REGN's asset turnover comes in at 0.683 -- ranking 43rd of 681 Pharmaceutical Products stocks.
  • JAZZ, AGLE, and VERU are the stocks whose asset turnover ratios are most correlated with REGN.

The table below shows REGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.683 0.868 0.456
2021-03-31 0.562 0.868 0.315
2020-12-31 0.536 0.868 0.292
2020-09-30 0.540 0.880 0.283
2020-06-30 0.543 0.882 0.282
2020-03-31 0.553 0.897 0.221

REGN Price Target

For more insight on analysts targets of REGN, see our REGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $683.25 Average Broker Recommendation 1.52 (Moderate Buy)

Regeneron Pharmaceuticals Inc. (REGN) Company Bio

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester CountyNew York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors. (Wikipedia:Source)

REGN Latest News Stream

Event/Time News Detail
Loading, please wait...

REGN Latest Social Stream

Loading social stream, please wait...

View Full REGN Social Stream

Latest REGN News From Around the Web

Below are the latest news stories about REGENERON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate REGN as an investment opportunity.

EyePoint sees stock surge on AMD drug trial data

The biotech said Phase 2 study results showed its experimental medicine for age-related macular degeneration was "non-inferior" to Regeneron's Eylea.

Yahoo | December 4, 2023

GOOG Stock Alert: Alphabet Is Spending Money in All the Wrong Places

The company continues to buy back Alphabet stock in large quantities.

Will Ashworth on InvestorPlace | December 2, 2023

JP Morgan’s Top 15 Stock Picks for 2023 and Now

In this piece, we will take a look at JP Morgan’s top 15 stock picks for 2023 and most recent stock picks. If you want to skip our introduction to the world’s biggest bank in terms of assets, its latest performance, and other details, then check out JP Morgan’s Top 5 Stock Picks for 2023. […]

Yahoo | December 2, 2023

Regeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio

TARRYTOWN, N.Y., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and simultaneous webcast to provide an update on the company's hematology portfolio on Thursday, December 14, 2023 at 8:30 AM ET. This investor call follows Regeneron data updates presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, from December 9-12, 2023. The webcast may be accessed from the "Investors & Media" page of Regeneron's w

Yahoo | November 30, 2023

Biotech And Healthcare Portfolio Playbook For December 2023/24

We are having a great but choppy market recovery over the past four weeks and it looks like it should continue through to the next earnings cycle in January. | November 27, 2023

Read More 'REGN' Stories Here

REGN Price Returns

1-mo 0.98%
3-mo 1.85%
6-mo 12.59%
1-year 12.45%
3-year 70.69%
5-year 125.45%
YTD 16.50%
2022 14.25%
2021 30.72%
2020 28.66%
2019 0.53%
2018 -0.65%

Continue Researching REGN

Want to see what other sources are saying about Regeneron Pharmaceuticals Inc's financials and stock price? Try the links below:

Regeneron Pharmaceuticals Inc (REGN) Stock Price | Nasdaq
Regeneron Pharmaceuticals Inc (REGN) Stock Quote, History and News - Yahoo Finance
Regeneron Pharmaceuticals Inc (REGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!